Comparing the general practice research database and the UKepilepsy and pregnancy register as tools for postmarketing teratogen surveillance: A nticonvulsants and the risk of major congenital malformations

Drug Safety

Volumn 34, Issue 2, 2011, Pages 157-171

  Charlton, Rachel A ^a   Weil, John G ^b   Cunnington, Marianne C ^b   Ray, Sayantani ^c   De Vries, Corinne S ^a  

^a University of Bath   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c GlaxoSmithKline Pharmaceuticals Ltd   (India)

Author keywords

Antiepileptic drugs, adverse reactions; Carbamazepine, adverse reactions; Computers; Congenital abnormalities, drug induced; Epilepsy; Lamotrigine, adverse reactions; Postmarketing surveillance; Pregnancy; Teratogenesis; Valproic acid, adverse reactions.

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; BECLAMIDE; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ADOLESCENT; ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; CONGENITAL MALFORMATION; DATA BASE; EPILEPSY; EPILEPSY AND PREGNANCY REGISTER; FEMALE; FIRST TRIMESTER PREGNANCY; FOLLOW UP; GENERAL PRACTICE RESEARCH DATABASE; HUMAN; MONOTHERAPY; NEWBORN DEATH; POSTMARKETING SURVEILLANCE; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TERMINATION; PRIORITY JOURNAL; REGISTER; RISK FACTOR; SPINA BIFIDA; STILLBIRTH; TERATOGENICITY; UNITED KINGDOM;

ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ADULT; ANTICONVULSANTS; DATABASES, FACTUAL; EPILEPSY; FEMALE; GENERAL PRACTICE; GREAT BRITAIN; HUMANS; INFANT, NEWBORN; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; PRODUCT SURVEILLANCE, POSTMARKETING; REGISTRIES; RISK; TERATOGENS; YOUNG ADULT;

EID: 78751612813     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11584970-000000000-00000     Document Type: Article

References (31)

1. Honein MA, Paulozzi LJ, Cragan JD, et al. Evaluation of selected characteristics of pregnancy drug registries. Teratology 1999; 60: 356-64
2. Schirm E, Meijer WM, Tobi H, et al. Drug use by pregnant women and comparable non-pregnant women in The Netherlands with reference to the Australian classification system. Eur JObstetGynecolReprod Biol 2004; 114 (2): 182-8
3. Lakha F,Glasier A. Unintended pregnancy and use of emergency contraception among a large cohort of women attending for antenatal care or abortion in Scotland. Lancet 2006; 368 (9549): 1782-7
4. Henshaw SK. Unintended pregnancy in the United States. Fam Plann Perspect 1998; 30 (1): 24-9
5. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med 1998; 338 (16): 1128-37
6. Mitchell A. Special considerations in studies of druginduced birth defects. In: Strom BL, editor. Pharmacoepidemiology. 3rd ed. Chichester: JohnWiley and Sons Ltd
7. Charlton RA, Cunnington MC, de Vries CS, et al. Data resources for investigating drug exposure during pregnancy and associated outcomes: the General Practice Research Database (GPRD) as an alternative to pregnancy registries. Drug Saf 2008; 31 (1): 39-51
8. Hardy JR, Holford TR, Hall GC, et al. Strategies for identifying pregnancies in the automated medical records of the General Practice Research Database. Pharmacoepidemiol Drug Saf 2004; 13: 749-59
9. Snowball JM, de Vries CS. Determination of pregnancy on the General Practice Research Database [abstract]. Pharmacoepidemiol Drug Saf 2007; 16: S118
10. Devine S, West S, Andrews E, et al. The identification of pregnancies within the General Practice Research Database. Pharmacoepidemiol Drug Saf 2010; 19 (1): 45-50
11. Hardy JR, Leaderer BP, Holford TR, et al. Safety of medications prescribed before and during early pregnancy in a cohort of 81 975 mothers from the UK General Practice Research Database. Pharmacoepidemiol Drug Saf 2006; 15: 555-64
12. Wurst KE, Ephross SA, Loehr J, et al. The utility of the general practice research database to examine selected congenital heart defects: a validation study. Pharmacoepidemiol Drug Saf 2007; 16: 867-77
13. Devine S, West SL, Andrews E, et al. Validation of neural tube defects in the full featured-general practice research database. Pharmacoepidemiol Drug Saf 2008; 17: 434-44
14. Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006; 77 (2): 193-8
15. Robert E, Guibaud P.Maternal valproic acid and congenital neural tube defects [letter]. Lancet 1982; II: 937
16. Lindhout D, Meinardi H. Spina bifida and in-utero exposure to valproate [letter]. Lancet 1984; II: 396
17. Dolk H, Jentink J, Loane M, et al., on behalf of the EUROCAT Antiepileptic Drug Working Group. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology 2008; 71: 714-22
18. Wood L, Martinez C. The General Practice Research Database: role in pharmacovigilance. Drug Saf 2004; 27 (12): 871-81
19. MHRA. The General Practice Research Database (2009) [online]. Available from URL: http://www.gprd.com/home/ default.asp [Accessed 2010 Mar 1]
20. Charlton RA, Weil JG, Cunnington MC, et al. Identifying major congenital malformations in the UK General Practice Research Database (GPRD): a study reporting on the sensitivity and added value of photocopied medical records and free text in the GPRD. Drug Saf 2010; 33 (9): 741-50
21. Hart AC, Hopkins CA, editors. ICD-9-CM professional for hospitals. Vol. 1, 2 and 3. International classification of diseases 9th revision, clinical modification. 6th ed. Reston (VA): Ingenix Inc., St Anthony Publishing/Medicode, 2003
22. EUROCAT. List of minor anomalies for exclusion up to birth year 2004 [online]. Available from URL: http://www. eurocat-network.eu/content/EUROCAT- Old-List-Minor- Anomalies.pdf [Accessed 2010 Feb 6]
23. EUROCAT. Minor anomalies for exclusion (chapter 3.2, guide 1.3) 2005 [online]. Available from URL: http://www. eurocat-network.eu/content/EUROCAT- Guide-1.3.pdf [Accessed 2010 Feb 6]
24. Kendle International Inc. The lamotrigine pregnancy registry: interim report, 1 September 1992 through 31 March 2009 [online]. Available from URL: http://pregnancyregistry. gsk.com/documents/lam-report-spring2009.pdf [Accessed 2010 Feb 6]
25. Mitchell A. Systematic identification of drugs that cause birth defects: a new opportunity. N Engl J Med 2003; 349 (26): 2556-9
26. Charlton RA, CunningtonM, Weil JG, et al. Regarding the need, or lack thereof, of a comparator group for pregnancy registries [letter]. Birth Defects Res A Clin Mol Teratol 2009; 85: 808
27. Samren EB, van Duijn CM, Christiaens GCML, et al. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999; 46: 739-46
28. Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999; 33 (2-3): 145-58
29. Wide K, Winbladh B, Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population- based register study. Acta Paediatr 2004; 93: 174-6
30. Wyszynski DF, Nambisan M, Surve T, et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005; 64 (6): 961-5
31. Vajda FJE, O'Brien T, Hitchcock A, et al. Antiepileptic drugs in pregnancy: great promise from pregnancy registries. J Clin Neurosci 2005; 10: 543-9